Fluorescent Light Energy ( FLE ) as an Adjunctive Therapy in Canine Cutaneous Epitheliotropic Lymphoma ( CTCL )
Veterinary Dermatology · 2026
DOI: 10.1111/vde.70098 ↗Kurz gefasst
Fachartikel in der Zeitschrift Veterinary Dermatology, 2026. Verfasst von S Nowell und 5 weiteren Autor:innen. Beteiligte Einrichtung: Animal Dermatology Clinic, Greenville, South Carolina, USA. Hauptthemen laut MEDLINE: Dog Diseases, Skin Neoplasms, Lymphoma, T-Cell, Cutaneous, Low-Level Light Therapy. Die Arbeit nennt 19 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Vetoquinol S.A..
Abstract (Originalsprache)
Background
Fluorescent light energy (FLE; Phovia, Vetoquinol) is a photobiomodulation therapy that promotes healing and reduces inflammation. Cutaneous epitheliotropic lymphoma (CTCL) is a neoplastic skin disease with limited treatment options. Although FLE is not considered genotoxic, its use in neoplastic conditions is off‐label. Hypothesis To assess the safety and clinical effect of FLE as an adjunctive treatment for canine CTCL. Animals Eight client‐owned dogs were diagnosed with CTCL via biopsy analysis and immunohistochemical analysis. Materials and Methods Each dog had one CTCL lesion treated with FLE with a lesion serving as a vehicle‐control. Treatments were administered weekly for 6 weeks, followed by 3 months follow‐up. Focal nodular lesions were assessed weekly using Response Evaluation Criteria of Solid Tumours (RECIST), while diffuse lesions were evaluated using the Canine Epitheliotropic Lymphoma Extent and Severity Index (CELESI). Owner‐perceived efficacy and quality of life were assessed using the Owner Global Assessment of Treatment Efficacy (OGATE) and a quality‐of‐life (QoL) survey.
Results
No statistically significant differences in estimated marginal means were observed between sites at any time point ( p > 0.05). Within‐subject analyses suggested more favourable lesion progression at FLE‐treated sites, and 75% of RECIST‐evaluated FLE lesions maintained stable disease. Diffuse FLE‐treated lesions demonstrated clinical severity reductions of ≤ 35.3%. Over 66% of owners rated treatment response as ‘fair’ to ‘excellent’ on the OGATE. One dog was withdrawn at Week 3 as a consequence of unrelated worsening. Conclusions and Clinical Relevance FLE appears to be a safe adjunctive therapy for canine CTCL, although statistically significant treatment effects were not demonstrated.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Animal Dermatology Clinic, Greenville, South Carolina, USA.
- Vetoquinol S.A., USA.
- Animal Dermatology Clinic, Portland, Oregon, USA.
ORCID-Profile: S Nowell
Förderung
- Vetoquinol S.A.
Zitieren
APA
Nowell, S., Fantini, O., Roman, A., Milley, C., Watson, J., & Bauer, C. (2026). Fluorescent Light Energy ( FLE ) as an Adjunctive Therapy in Canine Cutaneous Epitheliotropic Lymphoma ( CTCL ). Veterinary Dermatology. https://doi.org/10.1111/vde.70098
Vancouver
Nowell S, Fantini O, Roman A, Milley C, Watson J, Bauer C. Fluorescent Light Energy ( FLE ) as an Adjunctive Therapy in Canine Cutaneous Epitheliotropic Lymphoma ( CTCL ). Veterinary Dermatology. 2026. doi:10.1111/vde.70098
BibTeX
@article{Nowell2026,
author = {Nowell, S and Fantini, O and Roman, A and Milley, C and Watson, J and Bauer, C},
title = {Fluorescent Light Energy ( FLE ) as an Adjunctive Therapy in Canine Cutaneous Epitheliotropic Lymphoma ( CTCL )},
journal = {Veterinary Dermatology},
year = {2026},
doi = {10.1111/vde.70098}
}
EUVIMED